PROCTER & GAMBLE HEALTH | ADLINE CHEM LAB | PROCTER & GAMBLE HEALTH/ ADLINE CHEM LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | -129.7 | - | View Chart |
P/BV | x | 10.6 | - | - | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH ADLINE CHEM LAB |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
ADLINE CHEM LAB Mar-23 |
PROCTER & GAMBLE HEALTH/ ADLINE CHEM LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 11 | 47,190.9% | |
Low | Rs | 3,883 | 5 | 75,398.1% | |
Sales per share (Unadj.) | Rs | 740.7 | 0 | - | |
Earnings per share (Unadj.) | Rs | 138.2 | -7.2 | -1,910.0% | |
Cash flow per share (Unadj.) | Rs | 155.2 | -7.1 | -2,188.8% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | -2.7 | -16,710.8% | |
Shares outstanding (eoy) | m | 16.60 | 5.85 | 283.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 0 | - | |
Avg P/E ratio | x | 33.5 | -1.1 | -2,931.1% | |
P/CF ratio (eoy) | x | 29.8 | -1.2 | -2,557.4% | |
Price / Book Value ratio | x | 10.3 | -3.1 | -335.1% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 48 | 158,858.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 1 | 412,340.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 0 | - | |
Other income | Rs m | 184 | 10 | 1,848.2% | |
Total revenues | Rs m | 12,480 | 10 | 125,428.1% | |
Gross profit | Rs m | 3,247 | -51 | -6,314.3% | |
Depreciation | Rs m | 281 | 1 | 31,931.8% | |
Interest | Rs m | 8 | 0 | - | |
Profit before tax | Rs m | 3,142 | -42 | -7,420.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 0 | - | |
Profit after tax | Rs m | 2,295 | -42 | -5,419.7% | |
Gross profit margin | % | 26.4 | 0 | - | |
Effective tax rate | % | 27.0 | 0 | - | |
Net profit margin | % | 18.7 | 0 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 1 | 1,889,161.3% | |
Current liabilities | Rs m | 6,791 | 13 | 50,753.4% | |
Net working cap to sales | % | 40.0 | 0 | - | |
Current ratio | x | 1.7 | 0 | 3,722.2% | |
Inventory Days | Days | 263 | 0 | - | |
Debtors Days | Days | 343 | 0 | - | |
Net fixed assets | Rs m | 10,617 | 0 | - | |
Share capital | Rs m | 166 | 59 | 283.8% | |
"Free" reserves | Rs m | 7,265 | -74 | -9,794.4% | |
Net worth | Rs m | 7,431 | -16 | -47,418.6% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 1 | 3,601,564.5% | |
Interest coverage | x | 409.1 | 0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0 | - | |
Return on assets | % | 10.3 | -6,829.2 | -0.2% | |
Return on equity | % | 30.9 | 270.2 | 11.4% | |
Return on capital | % | 42.4 | 270.2 | 15.7% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 0 | - | |
Fx outflow | Rs m | 1,605 | 0 | - | |
Net fx | Rs m | -140 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 0 | 1,685,714.3% | |
From Investments | Rs m | -215 | NA | -2,150,000.0% | |
From Financial Activity | Rs m | -985 | NA | - | |
Net Cashflow | Rs m | 1,160 | 0 | 773,533.3% |
Indian Promoters | % | 0.0 | 29.6 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 0.0 | - | |
FIIs | % | 6.2 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 70.4 | 68.4% | |
Shareholders | 56,778 | 18,595 | 305.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | ADLINE CHEM LAB | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 0.00% | 0.45% |
1-Month | -1.15% | 0.00% | 2.55% |
1-Year | 0.73% | 405.00% | 56.14% |
3-Year CAGR | -8.76% | 72.10% | 15.22% |
5-Year CAGR | 4.97% | 31.26% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the ADLINE CHEM LAB share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of ADLINE CHEM LAB the stake stands at 29.6%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of ADLINE CHEM LAB.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
ADLINE CHEM LAB paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of ADLINE CHEM LAB.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.